Anaphore has entered into a partnership with Mitsubishi Tanabe Pharma Corporation to research, develop and commercialise novel protein therapies for autoimmune diseases.
The partnership will be built on Anaphore’s proprietary platform technology, which produces novel trivalent proteins called Atrimers, which have binding domains that can be used to bind to and activate or inhibit the target of interest.
Go deeper with GlobalData
Tanabe Research Laboratories, a subsidiary of Mitsubishi Tanabe Pharma, has the option to nominate two additional autoimmune targets for which Anaphore would develop potential protein therapeutics.
Under the agreement, Mitsubishi Tanabe Pharma will make a $5m upfront payment, and in addition, Anaphore will receive milestone payments totalling $110m and tiered royalties on sales.
The partnership will focus on biologic therapies for autoimmune disorders such as rheumatoid arthritis, inflammatory bowel disease and psoriasis.
Initial research activities will be undertaken by Tanabe Research Laboratories and Anaphore, while Mitsubishi Tanabe Pharma will be responsible for late-stage development and worldwide commercialisation.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalData
